title: CD44v6 expression in human skin keratinocytes as a possible mechanism for carcinogenesis associated with chronic arsenic exposure.
abstract: Inorganic arsenic is a well-known human skin carcinogen. Chronic arsenic exposure results in various types of human skin lesions, including squamous cell carcinoma (SCC). To investigate whether mutant stem cells participate in arsenic-associated carcinogenesis, we repeatedly exposed the HaCaT cells line to an environmentally relevant level of arsenic (0.05 ppm) in vitro for 18 weeks. Following sodium arsenic arsenite administration, cell cycle, colony-forming efficiency (CFE), cell tumorigenicity, and expression of CD44v6, NF-κB and p53, were analyzed at different time points (0, 5, 10, 15, 20, 25 and 30 passages). We found that a chronic exposure of HaCaT cells to a low level of arsenic induced a cancer stem- like phenotype. Furthermore, arsenic-treated HaCaT cells also became tumorigenic in nude mice, their growth cycle was predominantly in G2/M and S phases. Relative to nontreated cells, they exhibited a higher growth rate and a significant increase in CFE. Western blot analysis found that arsenic was capable of increasing cell proliferation and sprouting of cancer stem-like phenotype. Additionally, immunohistochemical analysis demonstrated that CD44v6 expression was up-regulated in HaCaT cells exposed to a low level of arsenic during early stages of induction. The expression of CD44v6 in arsenic-treated cells was positively correlated with their cloning efficiency in soft agar (r=0.949, P=0.01). Likewise, the expressions of activating transcription factor NF-κB and p53 genes in the arsenic-treated HaCaT cells were significantly higher than that in non-treated cells. Higher expressions of CD44v6, NF-κB and p53 were also observed in tumor tissues isolated from Balb/c nude mice. The present results suggest that CD44v6 may be a biomarker of arsenic-induced neoplastic transformation in human skin cells, and that arsenic promotes malignant transformation in human skin lesions through a NF-κB signaling pathway-stimulated expression of CD44v6.
authors.affiliation: Suzuka University of Medical Science, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Huang
authors.forename: S
authors.initials: S
authors.lastname: Guo
authors.forename: F
authors.initials: F
authors.lastname: Guo
authors.forename: Q
authors.initials: Q
authors.lastname: Yang
authors.forename: X
authors.initials: X
authors.lastname: Xiao
authors.forename: M
authors.initials: M
authors.lastname: Murata
authors.forename: S
authors.initials: S
authors.lastname: Ohnishi
authors.forename: S
authors.initials: S
authors.lastname: Kawanishi
authors.forename: N
authors.initials: N
authors.lastname: Ma
mesh_terms: D000818:Animals; D001151:Arsenic / Q000009:adverse effects / Q000494:pharmacology; D018053:Arsenites / Q000009:adverse effects* / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D002471:Cell Transformation, Neoplastic / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D018960:Hyaluronan Receptors / Q000096:biosynthesis*; D015603:Keratinocytes / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D016328:NF-kappa B / Q000378:metabolism; D009368:Neoplasm Transplantation; D014411:Neoplastic Stem Cells / Q000378:metabolism / Q000473:pathology / Q000637:transplantation; D012867:Skin / Q000378:metabolism / Q000473:pathology; D012878:Skin Neoplasms / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D017670:Sodium Compounds / Q000009:adverse effects* / Q000494:pharmacology; D014183:Transplantation, Heterologous; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: D018053:Arsenites; C112697:CD44v6 antigen; D004791:Enzyme Inhibitors; D018960:Hyaluronan Receptors; D016328:NF-kappa B; D017670:Sodium Compounds; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C017947:sodium arsenite; D001151:Arsenic
references.citation: Diagn Pathol. 2012 Jul 11;7:80
references.pmid: 22784357
references.citation: Cell. 1991 Apr 5;65(1):13-24
references.pmid: 1707342
references.citation: Ultrastruct Pathol. 2012 May;36(3):145-52
references.pmid: 22559040
references.citation: Nat Rev Cancer. 2008 Oct;8(10):755-68
references.pmid: 18784658
references.citation: Nat Rev Cancer. 2003 Dec;3(12):895-902
references.pmid: 14737120
references.citation: IARC Monogr Eval Carcinog Risks Hum. 2004;84:269-477
references.pmid: 15645578
references.citation: Acta Derm Venereol. 2010 Mar;90(2):141-6
references.pmid: 20169296
references.citation: Mol Cell Biochem. 2004 Jan;255(1-2):57-66
references.pmid: 14971646
references.citation: Eur J Histochem. 2011 Jun 07;55(2):e20
references.pmid: 22193299
references.citation: Eur J Histochem. 2011 Mar 16;55(1):e8
references.pmid: 21556123
references.citation: J Cell Biol. 1988 Mar;106(3):761-71
references.pmid: 2450098
references.citation: Environ Res. 2008 Sep;108(1):48-55
references.pmid: 18511031
references.citation: Toxicol Appl Pharmacol. 2007 Apr 1;220(1):18-24
references.pmid: 17289100
references.citation: Gynecol Oncol. 2007 Aug;106(2):400-6
references.pmid: 17512576
references.citation: Mutat Res. 1997 Jun;386(3):209-18
references.pmid: 9219559
references.citation: BMC Cancer. 2008 Feb 25;8:58
references.pmid: 18294404
references.citation: Br J Cancer. 2010 Aug 10;103(4):439-45
references.pmid: 20664590
references.citation: Nat Med. 2006 Mar;12(3):296-300
references.pmid: 16520777
references.citation: Blood. 1995 May 15;85(10):2885-99
references.pmid: 7537983
references.citation: J Invest Dermatol. 2010 Jul;130(7):1893-903
references.pmid: 20357818
references.citation: J Biol Chem. 2002 Feb 15;277(7):4589-92
references.pmid: 11717317
references.citation: Cell. 2007 Aug 24;130(4):597-600
references.pmid: 17719538
references.citation: Mol Carcinog. 2008 Jul;47(7):508-18
references.pmid: 18085531
references.citation: Mol Med. 2008 Jan-Feb;14(1-2):2-10
references.pmid: 18037969
references.citation: Oncogene. 2008 Oct 27;27(50):6507-21
references.pmid: 18955976
references.citation: Braz J Med Biol Res. 2006 May;39(5):677-85
references.pmid: 16648906
references.citation: Oncol Lett. 2012 May;3(5):1047-1051
references.pmid: 22783389
references.citation: BMC Biotechnol. 2009 Oct 05;9:84
references.pmid: 19804631
references.citation: Eur J Histochem. 2010 Feb 16;54(1):e3
references.pmid: 20353910
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):101-10
references.pmid: 20056628
references.citation: World J Gastroenterol. 2005 Nov 14;11(42):6601-6
references.pmid: 16425351
references.citation: Clin Cancer Res. 2010 Jun 15;16(12):3113-20
references.pmid: 20530701
references.citation: Chem Res Toxicol. 2004 Aug;17(8):1064-76
references.pmid: 15310238
references.citation: Crit Rev Oncol Hematol. 2002 Apr;42(1):5-24
references.pmid: 11923065
references.citation: Carcinogenesis. 2004 Aug;25(8):1535-42
references.pmid: 15059927
references.citation: Cancer Res. 1997 May 15;57(10):1991-8
references.pmid: 9157996
references.citation: Environ Health Perspect. 2010 Jan;118(1):108-15
references.pmid: 20056578
references.citation: J Obstet Gynaecol Res. 2006 Aug;32(4):379-86
references.pmid: 16882263
references.citation: Toxicol Appl Pharmacol. 2001 Oct 1;176(1):64-71
references.pmid: 11578149
references.citation: Toxicol Appl Pharmacol. 2001 May 1;172(3):249-61
references.pmid: 11312654
references.citation: Eur J Histochem. 2011 Mar 21;55(1):e7
references.pmid: 21556122
references.citation: Cell. 2007 Mar 9;128(5):837-40
references.pmid: 17350571
references.citation: Science. 2008 Mar 7;319(5868):1352-5
references.pmid: 18323444
references.citation: Am J Physiol Gastrointest Liver Physiol. 2009 May;296(5):G1060-8
references.pmid: 19264955
references.citation: Int J Cancer. 2013 Mar 1;132(5):1080-9
references.pmid: 22821376
references.citation: J Cell Physiol. 1995 Sep;164(3):605-12
references.pmid: 7544357
references.citation: Nature. 2001 Nov 1;414(6859):105-11
references.pmid: 11689955
references.citation: Int J Oncol. 2009 Aug;35(2):401-16
references.pmid: 19578756
references.citation: Eur J Cancer. 1995 Jul-Aug;31A(7-8):1110-2
references.pmid: 7577002
references.citation: Environ Health Perspect. 1992 Jul;97:259-67
references.pmid: 1396465
references.citation: Free Radic Biol Med. 2008 Sep 1;45(5):651-8
references.pmid: 18572023
references.citation: Annu Rev Cell Dev Biol. 2007;23:675-99
references.pmid: 17645413
references.citation: Virchows Arch. 2000 Mar;436(3):224-8
references.pmid: 10782880
references.citation: Environ Health Perspect. 2002 Oct;110 Suppl 5:749-52
references.pmid: 12426125
references.citation: Environ Health Perspect. 2000 Jul;108(7):655-61
references.pmid: 10903620
references.citation: J Cutan Pathol. 1995 Oct;22(5):407-12
references.pmid: 8594072
references.citation: Cancer Causes Control. 2010 May;21(5):745-57
references.pmid: 20084543